Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Clinical studies have demonstrated that for many, the combination of alternating weekly chemohormonal
therapies with Sr89 demonstrated a prolonged and progression-free survival.
Partridge AH, Burstein HJ, Winer EP (2001) Side effects of chemotherapy and combined chemohormonal
therapy in women with early-stage breast cancer.
Quality of life (QOL) analysis from CHAARTED: Chemohormonal
androgen ablation randomized trial in prostate cancer (E3805).
Biopharmaceutical company Medivation (NASDAQ:MDVN) and Astellas Pharma (TSE:4503) on Thursday jointly announced the launch of the ARCHES (AR Inhibition with ChemoHormonal
Therapy in Men with MEtastatic Castrate Sensitive Prostate Cancer) Phase III registrational trial under which the first patient has been randomised.
Phase III study of combined chemohormonal
therapy in metastatic prostate cancer (ECOG 3282): an Eastern Cooperative Oncology Group study.
Systemic adjuvant chemohormonal
therapies reduce ipsilateral breast tumour recurrence by approximately one-third [3-5] and hormonal therapies such as tamoxifen and aromatase inhibitors can decrease the risk of contralateral disease by more than 50% [6,7].
0 months for the initial hormonal therapy group and the chemohormonal
Clinical studies have demonstrated that the combination of alternating weekly chemohormonal
therapies with Sr-89 demonstrated a prolonged progression-free and overall survival with acceptable toxicity.
Legacy treatment can consist of surgery alone, surgery plus antihormonal therapy, or surgery plus chemohormonal
therapy, depending on the stage and hormone receptor status of the tumor.
Online  in hormone receptor-positive operable breast cancer and 0-3 positive axillary lymph nodes treated with adjuvant chemohormonal
therapy in a presentation by Lori Goldstein on behalf of the Eastern Cooperative Oncology Group (ECOG) and North American Cancer Intergroup (TBCI) (Abstr.
To help facilitate a comparison with the previously reported ECOG 3805: ChemoHormonal
Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) study, which stratified patients by high or low tumour volume, the investigators of the GETUG-AFU 15 study retrospectively assessed tumour volume and performed sub-analyses on these separate populations.